Difference between revisions of "Alaproclate"

Alaproclate
	File:Alaproclate structure.svg
Systematic (IUPAC) name
	1-(4-chlorophenyl)-2-methylpropan-2-yl 2-aminopropanoate
Clinical data
Routes of; administration	Oral
Legal status
Legal status	Uncontrolled;
Identifiers
CAS Number	60719-82-6 ; 60719-83-7 (hydrochloride)
ATC code	N06AB07 (WHO)
PubChem	CID 2081
ChemSpider	1997
Chemical data
Formula	C13H18ClNO2
Molar mass	255.740 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Latest revision as of 10:14, 20 September 2010

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Alaproclate (GEA-654) is a psychoactive drug and research chemical derived from zimelidine (Normud, Zelmid) that was being developed as an antidepressant by the Swedish pharmaceutical company Astra AB (now AstraZeneca) in the 1970s. It acts as a selective serotonin reuptake inhibitor (SSRI), and along with zimelidine and indalpine, was one of the first of its kind. Development was discontinued due to the observation of liver complications in rodent studies.

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

35px	This drug article relating to the nervous system is a stub. You can help ssf by expanding it. v d e

Revision as of 18:56, 27 July 2010 (view source) PotatoBot (Talk) m (Stub sorting and placement of stub template(s))	Latest revision as of 10:14, 20 September 2010 (view source) Jontas (Talk \| contribs) m (1 revision)
(No difference)